NCT03248284 Immune-Competent Cell Manifestations in Psoriatic Arthritis Achilles Tendons
| NCT ID | NCT03248284 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Odense University Hospital |
| Condition | Psoriatic Arthritis |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2017-08-21 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2017-08-21 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Tendon pathologies (enthesitis) are a characteristic component of psoriatic arthritis (PsA), and are observed in 35% to 50% of PsA patients. The Achilles tendon is one of the most commonly affected sites. This condition often causes great morbidity and loss of quality of life, and response only suboptimal to current intervention strategies. One of the main obstacles for the development of effective treatment methods is that the disease mechanisms remain poorly understood. To our knowledge, no one has yet ascertained the presence and function of immune-competent cells and inflammatory markers in tendons tissue from PsA patients suffering from Achilles enthesitis.
Eligibility Criteria
Inclusion Criteria: * Fulfilling the CASPAR criteria * Insertional Achilles tendon pain * Ultrasonic findings of inflammatory disease at the painful Achilles tendon insertion (= enthesitis) defined as abnormally hypoechoic (loss of normal fibrillar architecture) and/or thickened tendon at its bony attachment, seen in two perpendicular planes that may exhibit a Doppler signal or bony changes, including enthesophytes, and erosions. Exclusion Criteria: * Other inflammatory rheumatic diseases than PsA * Ultrasonic signs of complete rupture of the Achilles tendon * Not wishing to participate or not suited for project evaluation
Contact & Investigator
Maja S Kragsnaes, MD PhDfellow
PRINCIPAL INVESTIGATOR
Odense University Hospital
Frequently Asked Questions
Who can join the NCT03248284 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Psoriatic Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03248284 currently recruiting?
Yes, NCT03248284 is actively recruiting participants. Contact the research team at maja.kragsnaes@dadlnet.dk for enrollment information.
Where is the NCT03248284 trial being conducted?
This trial is being conducted at Odense, Denmark, Silkeborg, Denmark.
Who is sponsoring the NCT03248284 clinical trial?
NCT03248284 is sponsored by Odense University Hospital. The principal investigator is Maja S Kragsnaes, MD PhDfellow at Odense University Hospital. The trial plans to enroll 30 participants.